Want to see GB:RUA full AI Analyst Report?
RUA Stock Chart & Stats
14.00 p
-0.50 p(-3.85%)
At close: 4:00 PM EST
14.00 p
-0.50 p(-3.85%)
Day’s Range― - ―
52-Week Range10.42 p - 26.80 p
Previous CloseN/A
Volume378.53K
Average Volume (3M)148.53K
Market Cap
£11.79M
Enterprise Value10.21M
Total Cash (Recent Filing)£3.25M
Total Debt (Recent Filing)£794.00K
Price to Earnings (P/E)―
Beta0.21
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding62,060,272
10 Day Avg. Volume90,619
30 Day Avg. Volume148,527
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)0.98
Price to Sales (P/S)1.57
P/FCF Ratio-23.43
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Sustained Revenue ScalingMeaningful multi-year revenue growth indicates durable product-market fit and commercial traction in medtech and contract manufacturing. Scaling revenues support fixed-cost absorption, enable operational leverage, and make long-term profitability achievable if cost structure is controlled and demand persists.
High Gross MarginsA ~69% gross margin reflects differentiated product mix, manufacturing know-how, or pricing power in polymer/biomaterial solutions. High unit economics provide a durable buffer to cover operating expenses and fund R&D, improving the pathway to sustainable operating profitability over the medium term.
Conservative Capital StructureLow leverage and a solid equity base reduce refinancing and insolvency risk, giving the company flexibility to fund growth or manage cash burn with less interest strain. This balance-sheet strength is a durable advantage during scaling or cyclical industry phases.
Bears Say
Negative Operating & Free Cash FlowPersistently negative operating and free cash flow means the business does not self-fund its growth, increasing reliance on external capital or equity raises. Over months this can dilute shareholders, constrain reinvestment, and create execution risk if capital markets tighten or fundraising costs rise.
Ongoing Operating LossesDespite revenue growth and strong gross margins, negative EBIT indicates structural operating expense burdens or investment intensity exceed current margins. Without sustained operating-leverage gains or cost control, durable profitability remains uncertain and could delay value realization.
Negative Returns On EquityA negative ROE shows capital has not yet produced positive returns for shareholders, signaling that the firm is still converting investment into losses. Persisting negative returns can hinder investor confidence and make it harder to secure favorable capital for continued scaling.
RUA Life Sciences News
RUA FAQ
What was RUA Life Sciences’s price range in the past 12 months?
RUA Life Sciences lowest share price was 10.42 p and its highest was 26.80 p in the past 12 months.
What is RUA Life Sciences’s market cap?
RUA Life Sciences’s market cap is £11.79M.
When is RUA Life Sciences’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were RUA Life Sciences’s earnings last quarter?
Currently, no data Available
Is RUA Life Sciences overvalued?
According to Wall Street analysts RUA Life Sciences’s price is currently Overvalued.
Does RUA Life Sciences pay dividends?
RUA Life Sciences does not currently pay dividends.
What is RUA Life Sciences’s EPS estimate?
RUA Life Sciences’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does RUA Life Sciences have?
RUA Life Sciences has 62,060,272 shares outstanding.
What happened to RUA Life Sciences’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of RUA Life Sciences?
Currently, no hedge funds are holding shares in GB:RUA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
RUA Life Sciences
RUA Life Sciences plc, operating with its subsidiaries, delivers specialized polymers, various services, and finished products to the global medical device sector, spanning Europe, the United States, and other international markets. The company's operations encompass serving as a contract partner for the development and manufacturing of medical devices. Furthermore, it licenses its proprietary Elast-Eon and ECSil implantable co-polymers, which are integrated into cardiac and urological applications, including pacing leads, cardiac cannulae, and stent devices. RUA also grants licenses for its reaction injection molding technology, crucial for crafting high-precision medical device components. The firm is actively engaged in developing innovative bore polymer-sealed grafts, advanced soft tissue patches, and novel three-leaflet polymeric heart valves. Established in 1996 and based in Irvine, United Kingdom, the company adopted its current name, RUA Life Sciences plc, in June 2020, having previously been known as AorTech International plc.
Technical Analysis
Creo Medical
―
Genedrive
―
Inspiration Healthcare
―
OptiBiotix Health
―
Surgical Innovations
―
Options Prices
Currently, No data available
---